XML 49 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions and disposals (Tables)
 12 Months Ended
Jun. 30, 2018
Disclosure of detailed information about business combination [line items]  
Schedule of net assets disposed

The following table details the net assets disposed: 

 

 06.30.2018 

Investment properties   4,489 
Property, plant and equipment   29,001 
Intangible assets   7,108 
Investments in associates and joint ventures   401 
Restricted assets   91 
Trade and other receivables   12,240 
Investments in financial assets   2,846 
Derivative financial instruments   23 
Inventories   6,276 
Cash and cash equivalents   5,579 
TOTAL ASSETS   68,054 
Borrowings   21,310 
Deferred income tax liabilities   2,808 
Trade and other payables   23,974 
Provisions   447 
Employee benefits   1,279 
Salaries and social security liabilities   2,392 
Income tax and MPIT liabilities   8 
TOTAL LIABILITIES   52,218 
Non-controlling interest   7,335 
Net assets disposed including goodwill   8,501 
New Pharm Drugstores Ltd. [Member]  
Disclosure of detailed information about business combination [line items]  
Schedule of consideration and fair value of the acquired assets and the liabilities

The following table resumes consideration and fair value of the acquired assets and the liabilities assumed: 

 

December 2017

Fair value of identifiable assets and assumed liabilities:

 

 

 

Properties, plant and equipment   200 
Inventories   380 
Trade and other receivables   335 
Cash and cash equivalents   25 
Borrowings   (260)
Trade and other payables   (930)
Employee benefits   (25)
Provisions   (15)
Total net identifiable assets   (290)
Goodwill (pending allocation)   920 
Total   630 
Shufersal Ltd. [Member]  
Disclosure of detailed information about business combination [line items]  
Schedule of deconsolidated the subsidiary

Below are the details of the sale: 

 

 06.30.2018 

Cash received   6,420 
Remediation of the fair value of the remaining interest   13,164 
Total   19,584 
Net assets disposed including goodwill   (8,501)
Gain from the sale of a subsidiary, net of taxes (*)   11,083 

 

(*) Includes Ps. 2,643 as a result of the sale and Ps. 8,440 as a result of the remeasurement at the fair value of the new stake.